About Us
| Company Name | RIBOMIC Inc. |
|---|---|
| Address |
Shirokanedai Usui Bldg. 6F |
| Date Established | August 1, 2003 |
| President & CEO | Yoshikazu Nakamura（University of Tokyo Professor Emeritus） |
| Capital | JPY 63 Million (Capital surplus JPY 4,348 Million) (As of March, 2024) |
| Business Summary | Discovery and development of pharmaceutical compounds using RNA aptamers |
| Employees | 24（As of March, 2024） |
| Subsidiary | RIBOMIC USA Inc. CEO Yoshikazu Nakamura |
Board Members
Board Directors
| President and CEO | Yoshikazu Nakamura, PhD（University of Tokyo Professor Emeritus） |
|---|---|
| Business Administration Division CFO |
Hisato Oiwa |
| Board Directors R&D division, Discovery Research Department |
Tatsuo Adachi, PhD |
| Independent Board Director (outside) | Toshiaki Nishihata, PhD |
| Independent Board Director (outside) | Senya Matsufuji, MD PhD |
| Board Director (outside) | Toshinobu Fujiwara, PhD |
Audit & Supervisory Board Member
| Independent Auditor (full time and outside) |
Akiyuki Igarashi |
|---|---|
| Independent Auditor (outside) | Yutaka Yabe（certified public accountant） |
| Independent Auditor (outside) | Yasuhiro Fujii（attorney-at-law） |
Scientific Advisors
Robert B. Bhisitkul, PhD, MD
- Professor, Ophthalmology, University of California, San Francisco (UCSF) Medical Center
- Retina specialist
Pavel Krejčí, PhD
- School of Medicine, Masaryk University, Czech Republic
- FGF expert
Masatsugu Nakamura, PhD
- Santen Pharmaceutical Co., Ltd. former Head of Ophthalmic Research and Development Center
- Ophthalmic Therapeutics Development Specialist.
Our History
| August 2003 | Founded at Itabashi-ku, Tokyo. |
|---|---|
| March 2005 | The head office was moved to 3-15 Shirokanedai, Minato-ku, Tokyo. |
| June 2005 | Entered into a cooperative research agreement with The University of Tokyo on RNA aptamer drug discovery. |
| October 2006 | Entered into a non-exclusive license agreement with Archemix Corp. (USA) on the use of the SELEX patents focused on the IgG aptamer. |
| August 2007 | The head office was moved to 3-16 Shirokanedai, Minato-ku, Tokyo. |
| December 2007 | Entered into an exclusive license agreement with Archemix Corp. (USA) on the use of SELEX patents focused on the midkine aptamer. |
| January 2008 | Entered into a long-term collaboration research agreement with Otsuka Pharmaceutical Co., Ltd., for the development and marketing of RNA aptamer pharmaceuticals. |
| June 2008 | Entered into an exclusive license agreement with Archemix Corp. (USA) on the research licensing options. |
| February 2011 | Entered into an agreement on technical advice for RNA aptamer drug discovery with Zenyaku Kogyo Co., Ltd. |
| April 2012 | Installed the donation laboratory “RNA Medical Science” at The University of Tokyo Institute of Medical Science based on a multiyear cooperative research contract. |
| March 2014 | Entered into a multiyear cooperative research agreement with Taisho Pharmaceutical Co., Ltd., on therapeutic aptamer discovery. |
| April 2014 | Entered into an exclusive worldwide license agreement with Fujimoto Pharmaceutical Corporation for the anti-NGF aptamer. |
| September 2014 | Listed on the Tokyo Stock Exchange market Mothers (code: 4591). |
| March 2017 | Entered into a cooperative research agreement with Astellas Pharma Inc. |
| May 2017 | Entered into an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd., for the anti-midkine aptamer. |
| October 2018 | First dosing of RBM-007 in the world (SUSHI Study in the USA). |
| January 2019 | Entered into a cooperative research agreement with Vitamin C60 BioResearch Corporation |
| December 2019 | Initiated the phase 2 TOFU Study of RBM-007 for wet AMD in the USA. |
| March 2020 | Entered the license agreement with AJU pharma for RBM-007 in age-related macular degeneration. |
| July 2020 | Initiated the phase 1 study of RBM-007 for Achondroplasia in Japan. |
| October 2020 | Initiated the phase 2 RAMEN Extension Study of RBM-007 for wet AMD in the USA. |
| February 2021 | Entered into a Joint Research and Development Agreement with ASKA Pharmaceutical Co., Ltd. |
| July 2021 | Initiated the phase 2 TEMPURA IST of RBM-007 for wet AMD in the USA. |
| July 2022 | Initiated the observational study for continuous phase 2 trial of RBM-007 for Achondroplasia. |
| January 2023 | Initiated the phase 2 trial of RBM-007 for Achondroplasia. |
| October 2023 | Entered into a Joint Research and Development Agreement with Ajinomoto Co.,Inc. |
| December 2023 | Initiated the phase 2 extention trial of RBM-007 for Achondroplasia. |
Access
RIBOMIC Inc.
Shirokanedai Usui Building 6F (Front Desk)
3-16-13 Shirokanedai, Minato-ku, Tokyo 108-0071 Japan
Shirokane Station on Nanboku Line and Mita Line
Three-minute walk from the Shirokanedai Station
Take the #1 Exit and walk 200 meters toward Meguro passing by the Don Quixote store. The Building has spiral stairs onto the street with the “白金台鈴薬局” (Shirokanedai Suzu Pharmacy shop) on the first floor. The entrance is located on the side of the building about 20m ahead.